Surface modified receptor mediated delivery systems for site specific treatment of cancer
Keywords:Drug Delivery, Cancer, site-specific treatment
The treatment of the cancer has many challenges now a days due to side effects of the treatment. However, in the modern formulation development the concept of the site specific drug delivery for disease treatment in the body is considering as continuous challenges. Observing the challenges in convectional technique site specific drug delivery system has good potential to reduce adverse side effects, efficiently improve the human body health with very low toxicity. This review article elaborates the current challenges and prospective of surface modified drug carrier systems for delivery of protein for site-specific treatment of cancer and anti-cancer drug.
Saul JM, Annapragada A, Natarajan J V., Bellamkonda R V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Release, 92, 49–67 (2003).
Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 86, 215–23 (2009).
Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int. J. Pharm., 154, 123–40 (1997).
Oku N. Anticancer therapy using glucuronate modified long-circulating liposomes. Adv. Drug Deliv. Rev., 40, 63–73 (1999).
Oake A, Bhatt P, Pathak Y V. Understanding Surface Characteristics of Nanoparticles. Surface Modification of Nanoparticles for Targeted Drug Delivery. Springer International Publishing, pp.1–17 (2019).
Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Langer K, Dreis S, Asmussen B, Kreuter J, Gelperina S. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. Int. J. Pharm., 337, 346–56 (2007).
Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, Pathak Y V. Surface Modification of Nanoparticles for Targeted Drug Delivery. Surface Modification of Nanoparticles for Targeted Drug Delivery. Springer International Publishing, pp.19–31 (2019).
Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 56, 1649–59 (2004).
Singh HD, Wang G, Uludaǧ H, Unsworth LD. Poly-L-lysine-coated albumin nanoparticles: Stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics. Acta Biomater., 6, 4277–84 (2010).
Shen ZY, Ma GH, Dobashi T, Maki Y, Su ZG. Preparation and characterization of thermo-responsive albumin nanospheres. Int. J. Pharm., 346, 133–42 (2008).
Oyewumi MO, Mumper RJ. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int. J. Pharm., 251, 85–97 (2003).
Shen Z, Li Y, Kohama K, Oneill B, Bi J. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacol. Res., 63, 51–8 (2011).
Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells , Cancer Research, July, 2016, American Association for Cancer Research (AACR), pp.2065–2065.
Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, Mashru R. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J. Control. Release, 226, 148–67 (2016).
Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumor cells. J. Drug Target., 12, 461–71 (2004).
Bello L, Zhang J, Nikas DC, Strasser JF, Villani RM, Cheresh DA, Carroll RS, Black PML. αvβ3 and αvβ5 Integrin expression in meningiomas. Neurosurgery, 47, 1185–95 (2000).
Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells, Cancer Research, July, 2016, American Association for Cancer Research (AACR), pp.2063–2063.
Dubey PK, Singodia D, Verma RK, Vyas SP. RGD modified albumin nanospheres for tumor vasculature targeting. J. Pharm. Pharmacol., 63, 33–40 (2011).
Malaviya M, Shiroya M. Systemic gene delivery using lipid envelope systems and its potential in overcoming challenges. Int. J. Pharm. Drug Anal., 9, 46–55 (2021).
Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II Trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol., 23, 6019–26 (2005).
Guan Z, Feng F, Li QL, Jiang Z, Shen Z, Yu S, Feng J, Huang J, Yao Z, Hawkins MJ. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J. Clin. Oncol., 25, 1038–1038 (2007).
Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem., 43, 791–800 (1995).
Streets J, Bhatt P, Bhatia D, Sutariya V. Sunitinib-loaded MPEG-PCL micelles for the treatment of age-related macular degeneration. Sci. Pharm., 88, 1–12 (2020).
Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and in Vitro Characterization. Assay Drug Dev. Technol., 17, 167–77 (2019).
Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech, 20, (2019).
Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches, Histol Histopathol, 2005.
Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumor cells. J. Microencapsul., 35, 204–17 (2018).
Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, Kore G, Misra A. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. J. Drug Deliv. Sci. Technol., 45, 334–45 (2018).
Bier H, Hoffmann T, Haas I, Van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother., 46, 167–73 (1998).
Normanno N, Pergameno M, Iannaccone A, De Luca A. Mechanisms of action of EGFR inhibitors. EGFR Inhibitors in Cancer Treatment. Future Medicine Ltd., pp.7–17 (2012).
Wong SF. Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther., 27, 684–94 (2005).
How to Cite
Copyright (c) 2021 Fenil Vanapariya, Miteshkumar Malviya, Shiroya Milankumar Nathabhai
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmaceutical Research (JOAPR) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.